AMAG Pharmaceuticals
AMAG
AMAG was delisted on the 13th of November, 2020.
170 hedge funds and large institutions have $408M invested in AMAG Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 59 increasing their positions, 60 reducing their positions, and 21 closing their positions.
77% more call options, than puts
Call options by funds: $13.5M | Put options by funds: $7.61M
33% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 21
2% more funds holding
Funds holding: 166 → 170 (+4)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2% less repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 60
22% less capital invested
Capital invested by funds: $523M → $408M (-$115M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
N
Nuveen
Charlotte,
North Carolina
|
+$7.46M |
| 2 |
AC
Armistice Capital
New York
|
+$5.22M |
| 3 |
Morgan Stanley
New York
|
+$3.85M |
| 4 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$3.78M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$2.56M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$10.7M |
| 2 |
Millennium Management
New York
|
-$3.58M |
| 3 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
-$2.6M |
| 4 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$2.47M |
| 5 |
Man Group
London,
United Kingdom
|
-$2.31M |
AMAG Hedge Fund Activity: Q2 2019 in Review
170 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in AMAG Pharmaceuticals (AMAG) for Q2 2019, worth a combined $408M — down 22% from $523M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new AMAG positions and 21 closed out — a net gain of 7 holders — while 59 added to existing stakes and 60 trimmed.
The largest buyer was Nuveen, opening a new position worth an estimated $7.46M. The largest seller was Vanguard Group, cutting an estimated $10.7M.
- 170 institutional investors held AMAG Pharmaceuticals (AMAG) as of Q2 2019, up from 166 in Q1 2019.
- Funds reported $408M of AMAG Pharmaceuticals stock for Q2 2019, down 22% quarter-over-quarter.
- 28 funds opened new AMAG Pharmaceuticals positions in Q2 2019 and 21 closed out, a net change of +7 holders.
- The largest AMAG Pharmaceuticals buyer in Q2 2019 was Nuveen, an estimated $7.46M added.
- The largest AMAG Pharmaceuticals seller in Q2 2019 was Vanguard Group, an estimated $10.7M sold.
Based on aggregated 13F filings for Q2 2019.